The antitumor function of Tumor Necrosis Factor (TNF): I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity

Journal of Experimental Medicine

Volumn 167, Issue 3, 1988, Pages 1067-1085

  Havell, Edward A ^a,b   Fiers, Walter ^a,b   North, Robert J ^a,b  

^a TRUDEAU INSTITUTE   (United States)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; CELL CULTURE; CYTOLOGY; DIARRHEA; FEMALE; HISTOLOGY; IMMUNOCOMPETENCE; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MOUSE; NONHUMAN; SARCOMA; TUMOR NECROSIS; TUMOR REGRESSION;

ANIMAL; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HEMORRHAGE; IMMUNOCOMPETENCE; INFUSIONS, INTRAVENOUS; INJECTIONS; MICE; MICE, INBRED A; MICE, INBRED C57BL; NECROSIS; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0023940875     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.167.3.1067     Document Type: Article

References (26)

1. Carswell, E. A., L.J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA. 72:3666.
2. Buetler, B., D. Greenwald, J. D. Hulmes, M. Chang, Y.-C. E. Pan, J. Mathison, R. Ulevitch, and A. Cerami. 1986. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature (Lond.). 316:552.
3. Buetler, B., and A. Cerami. 1986. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature (Lond.). 320:584.
4. Shiral, T., H. Yamaguchi, H. Ito, C. W. Todd, and R. B. Wallace. 1985. Cloning and expression of the gene for human tumor necrosis factor. Nature (Lond.). 313:803.
5. Pennica, D., G. E. Nedwin, J. S. Hayflick, P. H. Seeburg, R. Derynck, M. A. Palladino, W.J. Kohr, B. B. Aggarwal, and D. V. Goeddel. 1984. Human tumor necrosis factor: p precursor structure, expression and homology to lymphotoxin. Nature (Lond.). 312:724.
6. Wang, A. M., A. A. Creasey, M. B. Ladner, L. S. Lin, J. Strickler, J. N. Van Arsdell, R. Yamamoto, and D. F. Mark. 1985. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (Wash. DC). 228:149.
7. Tavernier, J., L. Fransen, A. Marmenout, J. Van Der Heyden, R. Mueller, M-R. Ruysschaert, A. Van Vliet, R. Bauvdem, and W. Fiers. 1987. Isolation and expression of the genes coding for mouse and human tumor necrosis factor (TNF) and biological properties of recombinant TNF. In Lymphokines. Vol. 13. D. R. Webb and D. V. Goeddel, editors. Academic Press, New York. 181-198.
8. Fransen, L., R. Muller, A. Marmenout, J. Tavernier, J. Van der Heyden, E. Kawash-ima, A. Chollet, R. Tizard, H. Van Heuverswyn, A. Van Uliet, M. R. Ruysschaert, and W. Fiers. 1985. Molecular cloning of mouse tumor necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res. 13:4417.
9. Green, S., A. Dobrjansky, A. M.-A. Chiasson, E. Carswell, M. K. Schwartz, and L.J. Old. 1977. Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J. Natl. Cancer Inst. 59:1519.
10. Schear, M. J. 1944. Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide, f. Natl. Cancer Inst. 4:461.
11. Parr, I., E. Wheeler, and P. Alexander. 1973. Similarities of the antitumor actions of endotoxin, lipid A and double stranded RNA. Br. f. Cancer. 27:370.
12. Berendt, M. J., R. J. North, and D. P. Kirstein. 1978. The immunological basis of endotoxin-induced regression. Requirement for T cell-mediated immunity. J. Exp. Med. 148:1550.
13. Berendt, M. J., R.J. North, and D. P. Kirstein. 1978. The immunological basis of endotoxin-induced regression. Requirement for a pre-existing state of concomitant antitumor immunity. J. Exp. Med. 148:1560.
14. DiGiacomo, A., and R.J. North. 1987. Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly l+2" T cells are needed for endotoxin to cause regression of an established immunogenic tumour. Immunology. 60:367.
15. Havell, E. A., and G. L. Spitalny. 1983. Production and characterization of anti-murine interferon-gamma serum. J. Interferon Res. 3:191.
16. Algire, G. H., F. Y. Legallis, and H. D. Park. 1948. Vascular reactions of normal and malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marescens (Bacillus prodigeosus) culture filtrates. J. Natl. Cancer Inst. 8:53.
17. North, R.J. 1984. The therapeutic significance of concomitant antitumor immunity. Passive transfer of concomitant immunity with Ly-l+2-T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression. Cancer Immunol. Immunother. 18:75.
18. Bloksma, N., and F. M. A. Hofhuis. 1987. Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice. Cancer Immunol. Immunother. 25:165.
19. Palladinojr., M. A., M. R. Shalaby, S. M. Kramer, B. L. Ferraiolo, R. A. Baughman, A. H. Deleo, D. Crase, B. Marifino, B. B. Aggawal, I. S. Figari, D. Liggitt, and J. S. Patton. 1987. Characterization of the antitumor activities of human tumor necrosis factor-a and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 138:4023.
20. Nawroth, P. P., and D. M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740.
21. Sato, N., T. Goto, K. Haranaka, N. Satomi, H. Hariuchi, Y. Mano-Hirano, and Y. Sawasaki. 1986. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl. Cancer Inst. 76:1113.
22. Bevilacqua, M. P., J. S. Prober, G. R. Majeau, W. Fiers, R. S. Cotran, and M. A. Gimbrone, Jr. 1986. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc. Natl. Acad. Sci. USA. 83:4533.
23. Warren, B. A. 1979. The vascular morphology of tumors. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. H. I. Peterson, editor. CRC Press, Inc., Boca Raton, FL. 1-47.
24. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merriweather, S. Wolpe, S. M. Milsark, R. J. Hariri, T. J. Fahey, III, A. Zentella, J. D. Albert, G. T. Shires, and A. Cerami. 1986. Shock and tissue injury induced by recombinant human cachetin. Science (Wash. DC). 234:470.
25. Buetler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (Wash. DC). 229:869.
26. North, R. J., and E. A. Havell. 1988. The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J. Exp. Med. 167:1086.